Varying Rates of Hospital Reperfusion Therapy for Stroke: Insights From Analysis of National Stroke Audit Data
- PMID: 40955116
- PMCID: PMC12527578
- DOI: 10.5853/jos.2025.00360
Varying Rates of Hospital Reperfusion Therapy for Stroke: Insights From Analysis of National Stroke Audit Data
Abstract
Background and purpose: Disparities in stroke care exist globally. While reperfusion therapy is a standard treatment for acute ischemic stroke, variations in its implementation may exist across hospitals.
Methods: We analyzed data from 75,870 patients admitted to 247 acute stroke care hospitals across South Korea, sourced from the Acute Stroke Quality Assessment Program (2013-2018) by the Health Insurance Review and Assessment Service. The primary metric of interest was the hospital reperfusion therapy rate (RTR)-the proportion of patients who received intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT) among those potentially eligible for these therapies and had onset-to-arrival times ≤6 hours and initial National Institutes of Health Stroke Scale scores ≥4. We analyzed correlations between hospital RTRs, adjusted for age, sex, onset-to-arrival time, initial stroke severity, and hospital characteristics.
Results: Of the 10,513 patients eligible for reperfusion therapy, the overall RTR was 52.9%. The average hospital RTR was 34.8% with a median (interquartile range) of 37.5% (9.8-56.2). Hospitals with a greater number of beds and higher monthly stroke volume exhibited higher hospital RTRs. Factors such as monthly stroke volume, stroke unit availability, and monthly IVT and EVT case volume independently influenced hospital RTRs. Notably, hospitals with higher RTRs demonstrated reduced 1-year mortality, irrespective of stroke volume.
Conclusion: In a large national sample of acute stroke care hospitals, there was significant variability in hospital RTRs, with those having higher stroke volumes typically showing higher hospital RTRs. Additionally, an inverse correlation between hospital RTRs and 1-year mortality highlights the clinical importance of improving RTRs.
Keywords: Cerebrovascular disease; Health services research; Infarction; Outcome research; Stroke.
Conflict of interest statement
Philip B. Gorelick reports serving on the Steering Committee for a sphenopalatine ganglion stimulation trial and has received honoraria from Brainsgate, outside the submitted work. Hee-Joon Bae reports grants from Astrazeneca, Bayer Korea, Bristol Myers Squibb Korea, Chong Gun Dang Pharmaceutical Corp., Dong-A ST, Jeil Pharmaceutical Co., Ltd., Korean Drug Co., Ltd., Samjin Pharm, Takeda Pharmaceuticals Korea Co., Ltd., and Yuhan Corporation, and personal fees from Amgen Korea, Bayer, Daiichi Sankyo, JW Pharmaceutical, Hanmi Pharmaceutical Co., Ltd., Otsuka Korea, SK chemicals, and Viatris Korea, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose.
Figures
References
-
- Smith EE, Saver JL, Cox M, Liang L, Matsouaka R, Xian Y, et al. Increase in endovascular therapy in Get With The Guidelines-Stroke after the publication of pivotal trials. Circulation. 2017;136:2303–2310. - PubMed
-
- Menon BK, Saver JL, Goyal M, Nogueira R, Prabhakaran S, Liang L, et al. Trends in endovascular therapy and clinical outcomes within the nationwide Get With The Guidelines-Stroke registry. Stroke. 2015;46:989–995. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
